H 2 O 2 -mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: Potential role of lactate and ferritin

Cellular Physiology and Biochemistry

Volumn 25, Issue 6, 2010, Pages 767-774

  Deubzer, Beate ^a   Mayer, Florian ^a   Kuçi, Zyrafete ^a   Niewisch, Marena ^a   Merkel, Gisela ^a   Handgretinger, Rupert ^a   Bruchelt, Gernot ^b  

^a Department of General Paediatrics and Oncology/Haematology and ^*  (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Ferritin; H 2 O 2; Lactate; Neuroblastoma; Pharmacologic Ascorbate; Warburg Effect

Indexed keywords

ASCORBIC ACID; FERRITIN; GLUCOSE; HYDROGEN PEROXIDE; IRON; LACTIC ACID; CYTOTOXIN;

ACIDITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DETOXIFICATION; GLYCOLYSIS; HUMAN; HUMAN CELL; MICROENVIRONMENT; NEUROBLASTOMA; NEUROBLASTOMA CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SENSITIVITY ANALYSIS; METABOLISM; TUMOR CELL LINE;

ASCORBIC ACID; CELL LINE, TUMOR; CYTOTOXINS; FERRITINS; HUMANS; HYDROGEN PEROXIDE; LACTIC ACID; NEUROBLASTOMA;

EID: 77952963702     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315098     Document Type: Article

References (42)

1. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer. Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976;73:3685-3689.
2. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538-4542.
3. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, RubinJ, Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979;301:687-690.
4. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM: High dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312:137-141.
5. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-13609.
6. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M: Ascorbate in pharmacological concentrations selectively generates ascor-bate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007;104:8749-8754.
7. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh BD, Drisko J, Levine M: Pharmacologic doses of ascorbate act as prooxidant and decrease growth of aggressive tumour xenografts in mice. Proc Natl Acad Sci USA 2008;105:11105-11109.
8. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004;140:533-537.
9. Frei B, Lawson S: Vitamin C and cancer revisited. Proc Natl Acad Sci USA 2008;105:11037-11038.
10. Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009;47:32-40.
11. Robitaille L, Mamer OA, Miller WH Jr, Levine M, Assouline S, Melnychuk D, Rousseau C, Hoffer LJ: Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism 2009;58:263-269.
12. Warburg O, Posener K, Negelein E: Über den Stoffwechsel von Tumoren. Biochem Z 1924;152:319-344.
13. Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
14. Blatt J, Huntley D, Eagon PK: Synthesis of ferritin by neuroblastoma. Cancer Biochem Biophys 1990;11:169-176.
15. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA: A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004;10:4-12.
16. Hann HW, Levy HM, Evans AE: Serum ferritin as a guide to therapy in neurob-lastoma. Cancer Res 1980;40:1411-1413.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
18. Thurman R G, Ley HG, Scholz, R: Hepatic microsomal ethanol oxidation. Hydrogen peroxide formation and the role of catalase. Eur J Biochem 1972;25:420-430.
19. Halliwell B, Gutteridge JMC: Free radicals in biology and medicine, ed 4. Oxford, Oxford Univ. Press, 2007.
20. Selig RA, Madafiglio J, Haber M, Norris MD, White L, Stewart BW: Ferritin production and desferrioxamine cytotoxic-ity in human neuroblastoma cell lines. Anticancer Res 1993;13:721-725.
21. Thomas CE, Morehouse LA, Aust SD: Ferritin and superoxid-dependent lipid peroxidation. J Biol Chem 1985;260:3275-3280.
22. Biemond P, Swaak AJ, Beindorff CM, Koster JF: Superoxide-dependent and-independent mechanisms of iron mobolization from ferritin by xanthine oxidase. Implications for oxygen-free-radical-induced tissue desrtuction during ischemia and inflammation. Biochem J 1986;239:169-173.
23. Baader SL, Bruchelt G, Handgretinger R, Niethammer D: A simple assay for determination of iron release from ferritin in neuroblastoma cells. J Biochem Biophys Methods 1992;25:11-15.
24. Baader SL, Bruchelt G, Carmine TC, Lode HN, Rieth AG, Niethammer D: Ascorbic acid mediated iron release from cellular ferritin and its relation to DNA strand break formation in neuroblastoma cells. J Cancer Res Clin Oncol 1994;120:415-421.
25. Baader SL, Bill E, Trautwein AX, Bruchelt G, Matzanke B: Mobilization of iron from cellular ferritin by ascorbic acid in neu-roblastoma SK-N-SH cells: an EPR study. FEBS Lett 1996;381:131-134.
26. Herbert V, Shaw S, Jayatilleke E: Vitamin C-driven free radical generation from iron. J Nutr 1996;126:1213-1220.
27. 2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH. Cancer Res 1991;51:6066-6072.
28. Lode HL, Bruchelt G, Zinsser D, Baader SL, Rieth AG, Schade UF, Niethammer D: Ascorbic acid induces lipid peroxidation on neuroectodermal SK-N-LO cells with high endogeneous ferritin content and loaded with Mab-ferritin immunoconjugates. Anticancer Res 1994;14:1903-1906.
29. Kiessling M-K, Klemke CD, Kamiñski MM, Galani IE, Krammer PH, Gülow K: Inhibition of constitutively activated nuclear factor-κB induces reactive oxygen species-and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 2009;69:2365-2374.
30. Garber K: Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst 2004;96:1805-1806.
31. Kim JW, Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-8930.
32. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.
33. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nature Rev Cancer 2004;4:891-899.
34. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.
35. •- -generation. Apoptosis 2005;10:359-368.
36. Le A, Cooper ChR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang ChiV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107:2037-2042.
37. Duconge J, Miranda-Massari JR, Gonzales MJ, Jackson JA, Warnock W, Riordan NH: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J 2008;27:7-19.
38. Levine M, Espey MG, Chen Q: Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic Biol Med 2009;47:27-29.
39. Borst P: Mega-dose vitamin C as therapy for human cancer? Proc Natl Acad Sci USA 2008;105:E95.
40. Frei B, Lawson S, Levine M, Chen Q, Espey MG: Reply to Borst: Randomized clinical trials of high dose intravenous vitamin C in cancer patients are warranted. Proc Natl Acad Sci USA 2008;105:E96.
41. Gatenby RA: A change of strategy in the war of cancer. Nature 2009;459:508-509.
42. Gatenby RA, Silva AS, Gillies RJ, Frieden BR: Adaptive therapy. Cancer Res 2009;69:4894-4903.